ArticleDiabetes, obesity & metabolism2026
Ten-Year Cost-Effectiveness of the Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) Relative to Usual Care in Hong Kong Public Primary Care: A Population-Based Cohort Study.
Article in Diabetes, obesity & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
aimsThe Risk Assessment and Management Programme-Diabetes Mellitus (RAMP-DM) is a multidisciplinary, protocol-driven, risk-stratified care model integrated into public primary care in Hong Kong for patients with type 2 diabetes mellitus (T2DM). This study evaluated the real-world 10-year cost-effectiveness of RAMP-DM from the public healthcare provider perspective. MATERIALS AND
methodsProgramme costs from 2009 to 2019 were estimated using costing questionnaires and reported in 2019 US dollars. Direct medical costs were compared between patients enrolled in RAMP-DM and a propensity-score matched cohort receiving usual care only. Effectiveness was based on previously published 10-year estimates of absolute risk reduction in complications and all-cause mortality. The primary outcome was the incremental total direct medical cost per diabetes-related complication avoided over 10 years. Secondary outcomes included incremental cost per all-cause mortality avoided and programme cost per complication avoided. Sensitivity analyses examined the effects of parameter uncertainty and discounting.
resultsA total of 36 746 patients (18 373 in each group) were included. RAMP-DM was associated with absolute risk reductions of 12.1% for any complications and 16.2% for all-cause mortality. Accounting for the programme cost of US$329 per participant, total undiscounted direct medical costs over 10 years was US$10 543 lower per person among RAMP-DM participants (RAMP-DM: $23 430; usual care: US$33 973). RAMP-DM was a cost-saving strategy relative to usual care.
conclusionsRAMP-DM was associated with better 10-year clinical outcomes and lower direct medical costs. These findings support the economic value of structured multidisciplinary diabetes management programmes in publicly funded primary care settings, although residual confounding and uncertainty in cost estimates should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.